Navigation Links
Cardiome Initiates Phase 1 Study for GED-aPC
Date:11/20/2007

NASDAQ: CRME TSX: COM

VANCOUVER, Nov. 20 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) today announced initiation of subject dosing in its Phase 1 study of GED-aPC. The single-blinded, placebo-controlled, dose-ranging study will measure the safety, tolerability, pharmacokinetics and pharmacodynamics of GED-aPC in 24 healthy subjects, with each subject receiving a 15-minute loading dose at the start of a 24-hour continuous intravenous infusion of GED-aPC. Results from this study are expected in the first half of 2008.

"We are very pleased to initiate our clinical program for GED-aPC, an exciting addition to our clinical pipeline," stated Bob Rieder, Chairman and Chief Executive Officer of Cardiome. "We believe strongly that GED-aPC has the potential to be effective in treating a variety of cardiovascular diseases, and intend to aggressively advance this exciting new drug candidate through a rigorous clinical program."

GED-aPC is an engineered analog of recombinant human activated Protein C (aPC) with enhanced anti-inflammatory, anti-thrombotic and strong binding to endothelial protein C receptor properties, and has broad potential across multiple indications.

In April 2007 Cardiome acquired exclusive worldwide rights for GED-aPC for all indications. Cardiome intends to initially develop GED-aPC in cardiogenic shock, a life-threatening form of acute circulatory failure due to cardiac dysfunction, which is a leading cause of death for patients hospitalized following a heart attack.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two late-stage clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), a Phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C, and a pre-clinical program directed at improving cardiovascular function.

Vernakalant (iv)
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cardiome to Present at Bear Stearns Conference
2. Cardiome to Present at ThinkEquity Conference
3. Cardiome to Present at CIBC Conference
4. Cardiome To Release Third Quarter Results
5. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
6. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
7. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
8. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
9. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
10. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
11. Harbinger Research Initiates Coverage on HearAtLast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 04, 2015 Cook For Your ... that teaches healthy cooking to people touched by cancer, ... Lodge. The program, run by founder Ann Ogden, will ... Sport Management. The unique partnership will expand the program ... founded CFYL in 2007. After going through her own ...
(Date:3/4/2015)... 2015 Blake’s All Natural Foods ... will attend this year’s Natural Products Expo West in ... With this new line, Blake’s, who has the top ... continues its commitment to creating high-quality dishes that are ... in the natural channel, Blake’s understands what educated consumers ...
(Date:3/4/2015)... Alliance Healthcare Foundation (AHF), a non-profit organization working ... in San Diego and Imperial Counties, announced today that ... Grants program with awards totaling $1 million. , ... Support Grants program. Grant recipients were chosen through a ... committee, as well as the community as a whole. ...
(Date:3/4/2015)... 2015 As seen on Advanced ... can be a painful condition in which the lining ... the uterus leading to very unpleasant symptoms and complications ... have a terrible effect on women’s quality of life ... most common cause of infertility in women and carries ...
(Date:3/4/2015)... Farge, Wis. (PRWEB) March 04, 2015 Organic ... leading organic brand, today announced its cause campaign to Save ... gone viral and is making a difference to Bros everywhere. ... views on Youtube and Facebook. The video was named ... was featured in Forbes, Mashable and Digiday, among other media ...
Breaking Medicine News(10 mins):Health News:Drexel University and Cook for Your Life Team Up 2Health News:Drexel University and Cook for Your Life Team Up 3Health News:Drexel University and Cook for Your Life Team Up 4Health News:Drexel University and Cook for Your Life Team Up 5Health News:Fastest Growing Frozen Brand in Natural Channel Showcases New Line at Expo West 2015 2Health News:Fastest Growing Frozen Brand in Natural Channel Showcases New Line at Expo West 2015 3Health News:Alliance Healthcare Foundation Awards $1 million through Mission Support Grants Program 2Health News:Alliance Healthcare Foundation Awards $1 million through Mission Support Grants Program 3Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 3Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 2Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 3
... association between sleep problems and increased risk of fibromyalgia ... of sleep problems, and the association was stronger among ... of the prospective study, based on ten years of ... journal published by Wiley-Blackwell on behalf of the American ...
... FRANCISCO Patients with non-small cell lung cancer who have ... antifolate class of drugs, according to results of a recent ... and patients. "Our findings indicate that when patients ... they become very amenable to antifolate drugs," said lead researcher ...
... , SUNDAY, Nov. 13 (HealthDay News) -- Fibromyalgia patients ... six weeks reported improved memory function and less pain, ... finding is encouraging, it does not suggest a potential ... authors stressed. Senior author Dr. Brian Walitt, director ...
... Mann HealthDay Reporter , SUNDAY, Nov. 13 (HealthDay ... drug called Xarelto (rivaroxaban) may help people with "acute coronary ... stroke, a new study finds. Acute coronary syndrome is ... history of heart attack. The finding "opens up a ...
... California, San Diego School of Medicine and the UC ... drug discovery approach enabling the destruction of the most ... 13 online issue of the journal Nature Medicine ... fast-growing cancer cells without causing some of the negative ...
... scaling was associated with fewer heart attacks and strokes in ... Heart Association,s Scientific Sessions 2011. , Among more than 100,000 ... scaling) by a dentist or dental hygienist had a 24 ... risk of stroke compared to those who had never had ...
Cached Medicine News:Health News:Poor sleep habits linked to increased risk of fibromyalgia in women 2Health News:Antifolates show promise against NSCLC subtype 2Health News:Study Suggests Exercise May Help Memory of Fibromyalgia Patients 2Health News:Study Suggests Exercise May Help Memory of Fibromyalgia Patients 3Health News:Blood Thinner Xarelto Shows Promise for Heart Patients 2Health News:Blood Thinner Xarelto Shows Promise for Heart Patients 3Health News:Blood Thinner Xarelto Shows Promise for Heart Patients 4Health News:New way to target - and kill - proliferating tumors 2Health News:Professional dental cleanings may reduce risk of heart attack, stroke 2
(Date:3/4/2015)... Ill. , March 4, 2015 The March 3, ... of testosterone drugs must change their products, labels to clarify ... of heart attack and stroke is necessary to protect the ... Miracle , a partner at Simmons Hanly Conroy . ... indicate on labels that the products – currently taken by ...
(Date:3/4/2015)... KANSAS CITY, Kan. , March 4, 2015 /PRNewswire/ ... ), a pet therapeutics company focused on the licensing, ... animals, today announced that it will present at the ... March 10-12, 2015, at the Loews Miami Beach Hotel ... Steven St. Peter , M.D., President and ...
(Date:3/4/2015)...  Bayer HealthCare today announced that the U.S. ... company,s Biologics License Application (BLA) for BAY 81-8973, ... FDA approval of the investigational compound, proposed trade ... in children and adults. "Bayer ... hemophilia A patients who need them," said ...
Breaking Medicine Technology:Simmons Hanly Conroy, LLC: FDA Orders Label Warnings on Testosterone Drugs Concerning Normal Aging Use and Heart Attack-Stroke Risks 2Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3
... , May 24 Watson Pharmaceuticals, Inc. (NYSE: ... has received approval from the United States Food and Drug Administration ... USP, in the 500 and 1000 mg strengths, the generic equivalent ... product shortly.   , , ...
... May 24 ExpertRECALL, the leader in the field of recall ... study of recall logistics management in the food, drug and consumer products ... Mary Swartz with Michaels Stores, Inc. , ... Upon completion of their studies at Saint Louis ...
Cached Medicine Technology:Watson's Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval 2Watson's Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval 3ExpertRECALL Awards First Scholarships for Product-Safety Education 2
...
Pre-set guard for precise depth incision, bi-directional blade can cut left or right. 250 micron....
...
Tips are sharp on both sides to puncture, cut and tear the capsule...
Medicine Products: